RhumbLine Advisers’s Nuvectis Pharma NVCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$413K Buy
19,532
+2,261
+13% +$47.7K ﹤0.01% 2852
2026
Q2
$318K Buy
17,271
+8,614
+100% +$96.4K ﹤0.01% 3042
2026
Q1
$66.9K Buy
8,657
+224
+3% +$1.92K ﹤0.01% 3534
2025
Q4
$63.7K Sell
8,433
-2,897
-26% -$18.9K ﹤0.01% 3591
2025
Q3
$68.2K Sell
11,330
-1,348
-11% -$9.27K ﹤0.01% 3603
2025
Q2
$94.7K Buy
+12,678
New +$115K ﹤0.01% 3547
2024
Q3
– Sell
-1,871
Closed -$11.8K – 4288
2024
Q2
$11.8K Sell
1,871
-5,631
-75% -$38.3K ﹤0.01% 3959
2024
Q1
$61.5K Buy
7,502
+229
+3% +$1.95K ﹤0.01% 3578
2023
Q4
$60.7K Hold
7,273
– – ﹤0.01% 3581
2023
Q3
$93.7K Buy
7,273
+495
+7% +$7.17K ﹤0.01% 3485
2023
Q2
$108K Buy
+6,778
New +$108K ﹤0.01% 3498

Other funds holding NVCT

RhumbLine Advisers's NVCT Position: Q3 2026 in Review

RhumbLine Advisers increased its Nuvectis Pharma (NVCT) stake by 13% in Q3 2026, buying an estimated $47.7K and bringing the position to 19,532 shares worth $413K. The position accounts for ﹤0.01% of the portfolio, ranked #2852.

RhumbLine Advisers first reported a position in NVCT in Q2 2023 and has held it in 11 quarters since. 95 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

  • RhumbLine Advisers held 19,532 shares of Nuvectis Pharma worth $413K as of Q3 2026.
  • RhumbLine Advisers bought 2,261 Nuvectis Pharma shares in Q3 2026, an estimated $47.7K.
  • Nuvectis Pharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2852 holding.
  • RhumbLine Advisers first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 11 quarters since.
  • 95 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.